395 related articles for article (PubMed ID: 20307226)
1. Bosentan.
Mathier MA; Ishizawar D
Expert Opin Pharmacother; 2010 Apr; 11(6):1023-34. PubMed ID: 20307226
[TBL] [Abstract][Full Text] [Related]
2. Bosentan for the treatment of adult pulmonary hypertension.
Dwyer N; Kilpatrick D
Future Cardiol; 2011 Jan; 7(1):19-37. PubMed ID: 21174507
[TBL] [Abstract][Full Text] [Related]
3. Endothelin receptor antagonists for pulmonary arterial hypertension: an overview.
Raja SG
Cardiovasc Ther; 2010 Oct; 28(5):e65-71. PubMed ID: 20406243
[TBL] [Abstract][Full Text] [Related]
4. Bosentan therapy for pulmonary arterial hypertension.
Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
[TBL] [Abstract][Full Text] [Related]
5. Survival in patients with pulmonary arterial hypertension treated with first-line bosentan.
McLaughlin VV
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():10-5. PubMed ID: 16919005
[TBL] [Abstract][Full Text] [Related]
6. Bosentan: a review of its use in the management of mildly symptomatic pulmonary arterial hypertension.
Dhillon S; Keating GM
Am J Cardiovasc Drugs; 2009; 9(5):331-50. PubMed ID: 19791841
[TBL] [Abstract][Full Text] [Related]
7. Bosentan.
Chin K; Channick R
Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):175-82. PubMed ID: 15151466
[TBL] [Abstract][Full Text] [Related]
8. Current status of bosentan for treatment of pulmonary hypertension.
Raja SG; Dreyfus GD
Ann Card Anaesth; 2008; 11(1):6-14. PubMed ID: 18182753
[TBL] [Abstract][Full Text] [Related]
9. Bosentan treatment for pulmonary arterial hypertension related to connective tissue disease: a subgroup analysis of the pivotal clinical trials and their open-label extensions.
Denton CP; Humbert M; Rubin L; Black CM
Ann Rheum Dis; 2006 Oct; 65(10):1336-40. PubMed ID: 16793845
[TBL] [Abstract][Full Text] [Related]
10. Venous endotelin-1 (ET-1) and brain natriuretic peptide (BNP) plasma levels during 6-month bosentan treatment for pulmonary arterial hypertension.
Vizza CD; Letizia C; Petramala L; Badagliacca R; Poscia R; Zepponi E; Crescenzi E; Nona A; Benedetti G; Ferrante F; Sciomer S; Fedele F
Regul Pept; 2008 Nov; 151(1-3):48-53. PubMed ID: 18796317
[TBL] [Abstract][Full Text] [Related]
11. [Endothelin receptor antagonists in pulmonary arterial hypertension].
Tokgöz HC; Can MM; Kaymaz C
Anadolu Kardiyol Derg; 2010 Sep; 10 Suppl 2():9-15. PubMed ID: 20819750
[TBL] [Abstract][Full Text] [Related]
12. A retrospective study of bosentan in pulmonary arterial hypertension associated with congenital heart disease.
Durongpisitkul K; Jakrapanichakul D; Sompradikul S
J Med Assoc Thai; 2008 Feb; 91(2):196-202. PubMed ID: 18389984
[TBL] [Abstract][Full Text] [Related]
13. Bosentan in the treatment of pulmonary arterial hypertension with the focus on the mildly symptomatic patient.
Valerio CJ; Coghlan JG
Vasc Health Risk Manag; 2009; 5():607-19. PubMed ID: 19688101
[TBL] [Abstract][Full Text] [Related]
14. Endothelin receptor antagonists are an effective long term treatment option in pulmonary arterial hypertension associated with congenital heart disease with or without trisomy 21.
Kermeen FD; Franks C; O'Brien K; Seale H; Hall K; McNeil K; Radford D
Heart Lung Circ; 2010 Oct; 19(10):595-600. PubMed ID: 20728407
[TBL] [Abstract][Full Text] [Related]
15. Bosentan for chronic thromboembolic pulmonary hypertension.
Confalonieri M; Kodric M; Longo C; Vassallo FG
Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1503-12. PubMed ID: 19954311
[TBL] [Abstract][Full Text] [Related]
16. Optimizing endothelin receptor antagonist use in the management of pulmonary arterial hypertension.
Steiner MK; Preston IR
Vasc Health Risk Manag; 2008; 4(5):943-52. PubMed ID: 19183742
[TBL] [Abstract][Full Text] [Related]
17. First experience with an oral combination therapy using bosentan and sildenafil for pulmonary arterial hypertension.
Lunze K; Gilbert N; Mebus S; Miera O; Fehske W; Uhlemann F; Mühler EG; Ewert P; Lange PE; Berger F; Schulze-Neick I
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():32-8. PubMed ID: 16919008
[TBL] [Abstract][Full Text] [Related]
18. Combination of bosentan with epoprostenol in pulmonary arterial hypertension: BREATHE-2.
Humbert M; Barst RJ; Robbins IM; Channick RN; Galiè N; Boonstra A; Rubin LJ; Horn EM; Manes A; Simonneau G
Eur Respir J; 2004 Sep; 24(3):353-9. PubMed ID: 15358690
[TBL] [Abstract][Full Text] [Related]
19. Effects of long-term bosentan in children with pulmonary arterial hypertension.
Rosenzweig EB; Ivy DD; Widlitz A; Doran A; Claussen LR; Yung D; Abman SH; Morganti A; Nguyen N; Barst RJ
J Am Coll Cardiol; 2005 Aug; 46(4):697-704. PubMed ID: 16098438
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of bosentan for pulmonary arterial hypertension in adults with congenital heart disease.
Monfredi O; Griffiths L; Clarke B; Mahadevan VS
Am J Cardiol; 2011 Nov; 108(10):1483-8. PubMed ID: 21943933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
